Identification of CDK2 as a novel target in treatment of prostate cancer

Genetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progression

(2017) Yang Chen et al.   Scientific Reports

Cdk2 strengthens the intra-S checkpoint and counteracts cell cycle exit induced by DNA damage

(2017) Katarina Bačević et al.   Scientific Reports

Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis

(2016) Zhanzhan Xu et al.   MEDICAL ONCOLOGY

Identification of the miRNA–mRNA regulatory network in multiple sclerosis

(2016) Qinghe Yang et al.   NEUROLOGICAL RESEARCH

The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible

(2016) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

A CDK2 activity signature predicts outcome in CDK2-low cancers

(2016) S R McCurdy et al.   ONCOGENE

Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer

(2016) Po-Han Lin et al.   Oncotarget

ERK-mediated NF-κB activation through ASIC1 in response to acidosis

(2016) B Chen et al.   Oncogenesis

Cyclin-dependent kinase 2 (CDK2) is a key mediator for EGF-induced cell transformation mediated through the ELK4/c-Fos signaling pathway

(2015) C Peng et al.   ONCOGENE

Prostate cancer in Asian men

(2014) Kazuto Ito   Nature Reviews Urology

Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines

(2014) Tsui-Ting Ho et al.   NUCLEIC ACIDS RESEARCH

STRING v10: protein–protein interaction networks, integrated over the tree of life

(2014) Damian Szklarczyk et al.   NUCLEIC ACIDS RESEARCH

Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2

(2014) John M. Kokontis et al.   PLoS One

miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O

(2013) Binghai Chen et al.   JOURNAL OF CHEMOTHERAPY

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

(2013) Gwenaelle Gravis et al.   LANCET ONCOLOGY

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth

(2013) Eunjung Lee et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Negative Androgen-Response Elements Mediate Androgen-Dependent Transcriptional Inhibition of TGF- 1 and CDK2 Promoters in the Prostate Gland

(2011) W. Qi et al.   JOURNAL OF ANDROLOGY

CDK Inhibitors: From the Bench to Clinical Trials

(2010) Flavio Rizzolio et al.   CURRENT DRUG TARGETS

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

In prostate cancer C/EBPα promotes cell growth by the loss of interactions with CDK2, CDK4, and E2F and by activation of AKT

(2009) Hong Yin et al.   PROSTATE